R&D – Talk Bio

Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends

2 weeks ago talkbio0Tagged Bicycle, Financial cost, genentech, layoffs, Partnership, R&D, strategic realignment, Workforce reduction

Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment

Agentic AI is Here: Real-World Applications in Life Sciences & Healthcare (2025 Update)

2 weeks ago talkbio0Tagged agentic AI, Automation, Biological Science Disciplines, commercialization, Data Analysis, Health care facility, Pharma, Pharmacovigilance, Precision Medicine, R&D

Agentic AI; life sciences; healthcare; R&D; pharma; personalized medicine; pharmacovigilance; commercialization; automation; data analysis

BioNTech to Cut 90 More US Jobs Amid Strategic Realignment

2 weeks ago talkbio0Tagged BioNTech, Cambridge, Cell Therapy, Gaithersburg, layoffs, Market, pipeline focus, post-COVID, R&D, strategic alignment

BioNTech; layoffs; job cuts; R&D; pipeline focus; Gaithersburg; Cambridge; cell therapy; post-COVID market; strategic alignment

How Science Drives Better Business Decisions in Biopharma (2025 Update)

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biopharma, business strategy, data-driven decisions, decision science, digital twins, innovation, portfolio strategy, R&D

biopharma; decision science; AI; digital twins; R&D; portfolio strategy; data-driven decisions; innovation; business strategy

Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts

3 weeks ago talkbio0Tagged cost-cutting, Financial savings, Investments, Manufacturing, Merck & Co., R&D, restructuring, restructuring charges, Target

Merck & Co.; cost-cutting; $3 billion savings; restructuring; job cuts; 2027 target; restructuring charges; R&D; manufacturing investments

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

1 month ago talkbio0Tagged AstraZeneca, Chronic disease, Investments, Manufacturing, R&D, Surgical construction, tariffs, United States, Virginia plant

AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Biological Science Disciplines, Clinical Trials, Drug Discovery, Efficiency, Financial cost, Infrequent, R&D, trends qualifier

AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases

AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China, Chronic disease, Dosage Forms, Drug Discovery, GZMH gene, Investments, oral therapies, Partnership, R&D, research

AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment

ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

2 months ago talkbio0Tagged Antibody-Drug Conjugates, facility closure, layoffs, preclinical programs, R&D, restructuring, Solid Neoplasm, therapeutic autologous dendritic cells, UK, Zynlonta

ADC Therapeutics; layoffs; UK facility closure; biotech restructuring; R&D; antibody-drug conjugates; solid tumors; Zynlonta; preclinical programs

Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines

2 months ago talkbio0Tagged biotech partnership, cardiometabolic diseases, Collaboration, Deep Apple, G-Protein-Coupled Receptors, Nordisk, Obesity, Oral Medicine, R&D, small molecule therapeutics, Target

Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership